Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

1. Pneumococcal Disease and the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian Meta-Analysis of Observational and RCT Reports.Scientific reports · 2018
   Pooled it
2. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.PloS one · 2017
   Pooled it
3. Vaccines for the Elderly and Vaccination Programs in Europe and the United States.Vaccines · 2024
   Review
4. Discovery and Characterization of Pneumococcal Serogroup 36 Capsule Subtypes, Serotypes 36A and 36B.Journal of clinical microbiology · 2023
   Article
5. Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017-2018.Vaccine: X · 2023
   Article
6. Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals.Vaccine · 2020
   Article
7. [Antipneumococcal vaccination in Catalonian adults: Vaccine coverages and adequacy to distinct guideline recommendations].Atencion primaria · 2018
   Observational
8. Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations.Human vaccines & immunotherapeutics · 2018
   Review
9. Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?PharmacoEconomics · 2016
   Review
10. Determinants of tetanus, pneumococcal and influenza vaccination in the elderly: a representative cross-sectional study on knowledge, attitude and practice (KAP).BMC public health · 2016
    Article

Corrections and comments

• Comment on
  Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al.2014
• Comment on
  The stubborn persistence of adult pneumococcal pneumonia as a public health problem.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as